Cytomel (Liothyronine) History and Development

The Discovery of Triiodothyronine: 1950s Breakthrough

Before 1952, clinicians assumed thyroxine (T4) was the sole active thyroid hormone. That changed in a London laboratory. Jack Gross and Rosalind Pitt-Rivers at the National Institute for Medical Research identified triiodothyronine (T3) as a distinct, biologically active hormone with three to five times the metabolic potency of T4 [1]. Their paper in The Lancet confirmed that T3 circulated in human blood and bound nuclear receptors with far greater affinity than its four-iodine precursor [2].

The timing mattered. Edward Kendall and Charles Harington had already synthesized T4 in the 1920s and 1930s, but desiccated thyroid extract (a crude animal-derived preparation containing both T4 and T3) remained the dominant treatment for hypothyroidism through the mid-twentieth century [3]. Identifying T3 as a separate molecule opened two paths: synthetic production of each hormone individually and, eventually, the clinical question of whether patients need both.

Within four years of the Gross and Pitt-Rivers discovery, pharmaceutical chemists had synthesized liothyronine sodium. The compound received FDA approval in 1956 under NDA 008-186, marketed by Smith Kline & French (later acquired through a chain of mergers that brought the brand to Pfizer) [4]. Cytomel entered clinical use as both a standalone thyroid replacement and a diagnostic tool for the T3 suppression test, which measured thyroid autonomy before modern TSH assays existed.

How Liothyronine Works: Nuclear Receptor Binding and Genomic Action

Liothyronine binds thyroid hormone receptors (TR-alpha and TR-beta) in the cell nucleus with roughly ten-fold higher affinity than T4 [5]. This is the reason T3 acts faster and produces measurable metabolic effects within hours rather than days. T4 itself is largely a prohormone; approximately 80% of circulating T3 is generated peripherally through 5'-deiodination of T4 by type 1 and type 2 deiodinase enzymes (D1 and D2) [6].

Once bound to its nuclear receptor, T3 modulates transcription of genes controlling basal metabolic rate, cardiac output, thermogenesis, lipid metabolism, and neurocognitive function. The TR-beta isoform predominates in liver, kidney, and the pituitary gland, where it mediates the negative feedback loop that suppresses TSH secretion [5]. TR-alpha predominates in cardiac and skeletal muscle, which explains why supratherapeutic T3 doses produce tachycardia and tremor before other clinical effects become apparent.

A key pharmacokinetic distinction separates liothyronine from levothyroxine. T3 has a serum half-life of roughly 1 to 2 days compared with 6 to 7 days for T4 [7]. This shorter half-life produces a peak-to-trough fluctuation that makes once-daily dosing less physiologic than twice-daily administration. The peak serum T3 concentration after an oral dose of 25 mcg occurs approximately 2 to 4 hours post-ingestion and can transiently exceed the upper reference range, a pharmacokinetic limitation that has driven interest in sustained-release T3 formulations [8].

The Rise of Levothyroxine Monotherapy: Why T3 Lost Its Place

Throughout the 1950s and 1960s, clinicians prescribed liothyronine freely, often combined with T4 in fixed-ratio tablets (liotrix, marketed as Thyrolar). The pendulum shifted in the 1970s. Two developments displaced T3 from routine use.

First, the discovery of peripheral deiodination. In 1970, Sterling and colleagues demonstrated that the human body converts T4 to T3 enzymatically, meaning that exogenous T4 alone could, in theory, supply adequate T3 to all tissues [9]. Second, the introduction of sensitive TSH immunoassays in the 1980s gave clinicians a single, reliable metric for dose titration. Levothyroxine monotherapy became the standard because it was simpler to dose, had a long half-life permitting once-daily administration, and normalized TSH reliably [10].

By 1990, levothyroxine had become the most prescribed drug in the United States. The American Thyroid Association (ATA) endorsed T4 monotherapy as first-line treatment. Liothyronine and desiccated thyroid extract were relegated to the margins of thyroidology. But a problem persisted. Between 5% and 10% of hypothyroid patients treated with levothyroxine reported ongoing fatigue, cognitive difficulty, weight gain, and depressed mood despite biochemically normal TSH levels [11].

The Bunevicius Trial: Reopening the T3 Question

In 1999, Robertas Bunevicius and colleagues published a crossover trial in the New England Journal of Medicine that challenged the T4-only consensus [12]. The study enrolled 33 patients with hypothyroidism and replaced 50 mcg of their daily levothyroxine dose with 12.5 mcg of liothyronine for five weeks, then crossed them over to T4 monotherapy.

Results showed statistically significant improvements in mood, cognitive function (specifically on tests of attention and mental flexibility), and patient-reported well-being during the T3-containing phase. Serum lipid profiles also improved modestly. The authors concluded that "treatment with thyroxine plus triiodothyronine improved the quality of life of most patients" compared with thyroxine alone [12].

The trial was small but catalytic. It generated a wave of subsequent studies, not all of which replicated the findings. A 2006 meta-analysis by Grozinsky-Glasberg and colleagues pooled 11 randomized controlled trials (N=1,216) and found no consistent benefit of combination T4/T3 therapy over T4 monotherapy on measures of mood, cognition, or quality of life [13]. A European Thyroid Association (ETA) 2012 analysis reached similar conclusions at the population level but noted that a subgroup of patients, particularly those with specific deiodinase gene polymorphisms (DIO2 Thr92Ala), might respond preferentially to combination therapy [14].

Deiodinase Polymorphisms: A Pharmacogenomic Explanation

The DIO2 gene encodes the type 2 deiodinase enzyme responsible for converting T4 to T3 in the brain, pituitary, and skeletal muscle. A common single-nucleotide polymorphism (Thr92Ala, rs225014) occurs in approximately 16% of the population in homozygous form [15]. Carriers of this variant may have reduced intracellular T3 generation from T4 substrate, potentially explaining why some patients feel hypothyroid despite normal serum TSH and free T4 levels.

Panicker et al. published a study in the Journal of Clinical Endocrinology and Metabolism (2009) that found DIO2 Thr92Ala homozygotes reported greater psychological well-being on combination T4/T3 therapy compared with T4 alone [16]. The effect was absent in wild-type carriers. Dr. Colin Dayan, senior author on the study, stated: "This is the first evidence that a common genetic variation may determine which patients benefit from combination therapy" [16].

This pharmacogenomic angle remains under investigation. The ATA's 2014 guidelines on hypothyroidism treatment acknowledged the DIO2 polymorphism data but stopped short of recommending genotype-guided prescribing, citing insufficient evidence for clinical implementation [17]. The 2021 ETA guideline update, authored by Wiersinga and colleagues, adopted a similar position while calling for larger prospective trials stratified by DIO2 genotype [14].

Sustained-Release T3: Solving the Pharmacokinetic Problem

One persistent criticism of liothyronine is its peak-trough pharmacokinetic profile. A 25 mcg dose can produce supraphysiologic serum T3 levels within 2 to 4 hours, followed by a decline that may leave tissue T3 concentrations suboptimal by the following morning [8]. This pattern contrasts with normal thyroid physiology, where the gland secretes T3 continuously.

Celi et al. conducted a pharmacokinetic study at the National Institutes of Health in 2011 comparing immediate-release liothyronine with a compounded sustained-release formulation [18]. The sustained-release form produced a flatter T3 curve with a lower Cmax (peak concentration reduced by approximately 47%) and more stable 24-hour serum levels. TSH remained more stable across the dosing interval. The researchers concluded that sustained-release T3 more closely mimicked normal thyroid physiology.

No FDA-approved sustained-release liothyronine product exists as of 2026. Compounding pharmacies produce sustained-release T3 capsules, but these lack the bioequivalence testing and batch consistency of commercially manufactured products. The ATA's 2014 guidelines noted that an FDA-approved slow-release T3 preparation "would be a prerequisite for a definitive clinical trial of combination therapy" [17]. Several pharmaceutical companies have explored development programs, but none has advanced to a New Drug Application filing.

Liothyronine in Thyroid Cancer: Withdrawal Protocols and rhTSH

Liothyronine has a distinct role in differentiated thyroid cancer management independent of its use in hypothyroidism. Before recombinant human TSH (Thyrogen, rhTSH) became widely available in 1998, patients undergoing radioiodine ablation or whole-body scanning needed to achieve a TSH level above 30 mIU/L to stimulate iodine uptake by residual thyroid tissue [19].

Withdrawing levothyroxine alone required 4 to 6 weeks off medication, producing severe hypothyroid symptoms. The standard alternative involved switching patients from T4 to liothyronine for 2 to 4 weeks, then withdrawing liothyronine for 2 weeks. Because T3 has a shorter half-life, the total period of symptomatic hypothyroidism was compressed to roughly 2 weeks rather than 6 [19].

The 2015 ATA guidelines for thyroid cancer management endorsed rhTSH stimulation as an alternative to thyroid hormone withdrawal for both diagnostic scanning and remnant ablation in most patients, reducing the clinical need for T3 bridging protocols [20]. Liothyronine withdrawal remains relevant in settings where rhTSH is unavailable or contraindicated.

Current Guideline Positions and Ongoing Debate

The ATA's 2014 hypothyroidism treatment guidelines represent the most comprehensive English-language consensus on liothyronine use. The document states that levothyroxine monotherapy remains the standard of care but acknowledges that "a 3-month trial of combination LT4/LT3 therapy might be considered in compliant LT4-treated hypothyroid patients who have persistent complaints despite serum TSH values within the reference range" [17]. The recommended T4-to-T3 dose ratio is 13:1 to 20:1, reflecting the physiologic secretion ratio of the normal thyroid gland.

The British Thyroid Association (BTA) issued a 2023 position statement concluding that "current evidence does not support the routine use of liothyronine" but left the door open for specialist-supervised trials in patients with persistent symptoms and normal biochemistry [21]. The ETA's stance is similar, with guidelines emphasizing the need for informed consent and close monitoring of cardiac markers, bone density, and serum T3 levels during any combination therapy trial [14].

Prescribing data reveals a growing gap between guideline caution and clinical practice. A 2020 analysis of UK primary care data found that liothyronine prescriptions fell by 74% between 2015 and 2019, driven largely by a sharp price increase (from £4.46 to £258.19 per 28-day pack in the UK) rather than by changes in clinical evidence [22]. In the United States, generic liothyronine remained more affordable, and the National Prescription Audit reported approximately 2.8 million prescriptions dispensed in 2023 [23].

The Mechanism in Context: Why T3 Matters Beyond TSH

A normal thyroid gland produces roughly 85 mcg of T4 and 6.5 mcg of T3 daily [6]. Peripheral deiodination generates an additional 26 mcg of T3 from T4, yielding a total daily T3 production of approximately 32.5 mcg. The pituitary gland uses its own local D2 enzyme to convert T4 to T3, meaning that serum TSH primarily reflects pituitary T3 status rather than whole-body T3 availability.

This anatomic separation is the core argument advanced by proponents of combination therapy. A patient taking levothyroxine monotherapy may have a normal TSH because pituitary D2 activity is intact, while peripheral tissues with lower D2 expression (notably skeletal muscle and certain brain regions) may be relatively T3-deficient [15]. Serum free T3 levels in levothyroxine-treated patients are, on average, 10% lower than in age-matched euthyroid controls with intact thyroid glands [24].

Whether this 10% difference is clinically meaningful remains the central question in thyroidology. The Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism (TRUST) trial (N=737) found no benefit from levothyroxine therapy in older adults with mildly elevated TSH, raising broader questions about the threshold at which thyroid hormone insufficiency produces symptoms [25].

From Bench to Bedside: Seven Decades of Liothyronine

Liothyronine's arc from breakthrough molecule to marginalized drug to partial rehabilitation reflects the iterative nature of endocrine pharmacology. The drug itself has not changed since 1956. What has changed is the precision with which clinicians can identify the subset of patients who may benefit from exogenous T3, whether through DIO2 genotyping, serum T3-to-T4 ratio assessment, or systematic symptom evaluation using validated instruments like the ThyPRO questionnaire.

The next inflection point will likely come from a properly powered, genotype-stratified randomized trial of sustained-release liothyronine. The 2014 ATA guidelines called for exactly this study. As of 2026, it has not been conducted. Until it is, liothyronine prescribing will continue to occupy a space defined by individual clinical judgment, patient preference, and the gap between a normal TSH and how a patient actually feels.

Patients prescribed liothyronine should take the medication on an empty stomach, typically split into two daily doses 8 to 12 hours apart, with monitoring of serum free T3 (drawn before the morning dose) and TSH every 6 to 8 weeks during dose titration [17].